NEW HPV Testing: E6/E7 mRNA detection
(Test name: Probe Human PAP)

As of August 13, 2018, Geisinger Medical Laboratories will launch a new assay for the identification of women at risk of developing cervical carcinoma due to human papilloma virus (HPV).

Since the presence of HPV DNA (our earlier test method) does not confirm that cervical dysplasia or cervical cancer is present, or will develop, we are deploying a gene expression assay.

The assay will be performed at GMC and detects the upregulation of HPV genes (E6 and E7), which occurs prior to and during the development of cervical cancer. The assay offers a unique screening approach by targeting high-risk HPV messenger RNA (mRNA) from the E6/E7 oncogenes, a strategy that better correlates with the severity of the lesion compared to that of HPV DNA screening.

The assay offers the same sensitivity to HPV DNA-based tests with improved specificity and adds accuracy to detection when high viral loads of HPV DNA are present and may cause false negative PCR reactions.

CPT 87624

Transport = Room temperature in PreservCyt for 30d or SurePath for 21d

REMINDERS

- **Probe Human PAP (HPV E6/ E7 mRNA) replaces HPV DNA testing at Geisinger.**

- **Sample:** Cervical specimens in ThinPrep Pap Test vials containing PreservCyt Solution or in SurePath vials and collected with broom-type or cytobrush/spatula collection devices may be tested.